Block shares plunge 14% after Hindenburg Research report
Block said he is working with the SEC on how to "explore legal action against Hindenburg Research over the inaccurate ...
Tag: Plunge
Proterra shares plunge as revenue forecast lags estimates (NASDAQ:PTRA)
Proterra (NASDAQ:PTRA) share sunk 54% on Thursday after the commercial vehicle supplier reported fourth-quarter results that missed Wall Street estimates. ...
Stock futures plunge as market yearns for stability amid banking crisis
With the collapse of SVB, many commentators have echoed the dictum that no company is "too big to fail." Uncertainty ...
Natural gas stocks plunge as commodities fall 14% due to warmer US forecast (NYSEARCA:UNG)
straga/iStock via Getty Images Natural gas producers tumbled Monday after US natural gas prices fell by the biggest percentage since ...
Silvergate Bank Terminates Crypto Payments Network As Shares Plunge To All-Time Low – Top Bitcoin News
Silvergate Bank has discontinued its cryptocurrency payment network. The decision to shut down the Silvergate Exchange Network followed the withdrawal ...
5 Big Earnings Reports: Rivian, Novavax Plunge Into Broad Mistakes
© Reuters By Davit KirakosyanInvesting.com -- Here's your daily professional roundup of the top earners you may have missed at ...
Australia’s Star Entertainment sees up to $1.1 billion affected by tax change; Stocks plunge By Reuters
© Reuters. By Savyata Mishra (Reuters) - Australia's Star Entertainment Group said on Monday it expects to incur a non-cash ...
SOL, ADA Plunge, as Market Momentum Turns Bearish – Market Updates Bitcoin News
Solana fell to a three-week low on Feb. 10 as momentum in the cryptocurrency markets remained firmly bearish. As of ...
Bed Bath & Beyond shares plunge as retailer rolls the dice on $1 billion capital raise to avoid bankruptcy
"We expect that we will likely file for bankruptcy protection if the Transactions are not consummated," Bed Bath & Beyond ...
Aridis shares plunge ~25% as antibody drug fails Phase 3 trial in pneumonia
gorodenkoff Aridis Pharmaceuticals (NASDAQ:ARDS) AR-301 monoclonal antibody therapy failed the primary endpoint in a phase 3 trial to treat ventilator-associated ...
Recommended.
